Pharma: Page 14
-
Getty Images
Lilly names Mount Sinai scientist as first chief AI officer
Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.
By Ned Pagliarulo • Oct. 9, 2024 -
Getty Images
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.
By BioPharma Dive staff • Oct. 9, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Adobe Stock/ Rocketclips
Sponsored by NorstellaUsing de-identified lab data to find patients, target physicians and expedite treatment
Many pharma companies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.
By Madeline Naylor, DHSc, Vice President of Health Informatics, RWD, Norstella with Patrick Winniewicz, Executive Director of Healthcare Analytics Solutions, Quest Diagnostics • Oct. 9, 2024 -
Warren Little via Getty Images
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
By Delilah Alvarado • Oct. 8, 2024 -
GSK’s ViiV to expand supply of HIV drug in Africa
The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.
By Delilah Alvarado • Oct. 7, 2024 -
Getty Images
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
By BioPharma Dive staff • Oct. 4, 2024 -
Getty Images
FDA makes end of Zepbound, Mounjaro shortage official
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded counterparts.
By Kristin Jensen • Oct. 3, 2024 -
Scott Olson via Getty Images
Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing
With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.
By Kristin Jensen • Oct. 2, 2024 -
iStock via Getty Images
How Roche plans to fill a projected $8B sales gap
Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.
By Amy Baxter • Oct. 2, 2024 -
Retrieved from ASCO/Luke Franke 2024 on September 30, 2024
The top biopharma conferences remaining in 2025
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025.
By BioPharma Dive staff • Updated June 30, 2025 -
Getty Images
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
By BioPharma Dive staff • Oct. 1, 2024 -
Courtesy of Roche
Roche turns to a startup in search for new breast cancer drugs
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
By Jonathan Gardner • Sept. 30, 2024 -
Getty Images
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
By BioPharma Dive staff • Sept. 27, 2024 -
Getty Images
Pfizer to pull sickle cell drug from market, shut down trials
The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019.
By Kristin Jensen • Sept. 26, 2024 -
Mario Tama via Getty Images
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.
By Kristin Jensen • Sept. 25, 2024 -
Chip Somodevilla via Getty Images
Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs
CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.
By Jonathan Gardner • Sept. 24, 2024 -
Getty Images
Sponsored by AltasciencesThe golden era of GLP-1 drugs: Where we are and what comes next
GLP-1 drugs went from helping with blood sugar management to supporting weight loss. What’s next?
Sept. 23, 2024 -
Getty Images
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
By BioPharma Dive staff • Sept. 20, 2024 -
Getty Images
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
By BioPharma Dive staff • Sept. 18, 2024 -
Permission granted by AstraZeneca
Sanofi readies to meet US demand for RSV antibody
With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in full supply this RSV season.
By Delilah Alvarado • Sept. 16, 2024 -
Getty Images
Sponsored by SASGenerative AI can enhance pharmaceutical innovation – but are you ready for it?
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
By Susan Lenderts, Global Head of Life Sciences, SAS • Sept. 16, 2024 -
Maddie Meyer via Getty Images
Moderna, trailing rivals, checks its RSV shot expectations
During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.
By Delilah Alvarado • Sept. 13, 2024 -
Getty Images
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.
By BioPharma Dive staff • Sept. 13, 2024 -
Getty Images
Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic spontaneous urticaria.
By Kristin Jensen • Sept. 11, 2024 -
Getty Images
GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug
The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity drug data and Lilly appointed a company veteran as its new CFO.
By BioPharma Dive staff • Sept. 11, 2024
Previous
